Context Therapeutics Inc.
About Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$36.1M
- Total assets
- $68.5M
- Market cap
- $160.8M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Operating income
- -$39.7M
- Income tax
- $0
- Net income
- -$36.1M
- EPS (basic)
- $-0.38
- EPS (diluted)
- $-0.38
Balance sheet
- Total assets
- $68.5M
- Current assets
- $68.4M
- Total liabilities
- $8.0M
- Current liabilities
- $8.0M
- Shareholders’ equity
- $60.5M
Cash flow
- Operating cash flow
- -$26.4M
- Investing cash flow
- -$2.0M
- Financing cash flow
- -$15.3K
- Net cash flow
- -$28.4M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $160.8M
- EPS (diluted)
- $-0.38
- Shares outstanding
- 94.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 20, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $36.1M.
- Trading 49% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Context Therapeutics Inc..
Write a review
News about Context Therapeutics Inc.
News & sentiment via Polygon.io
